Sage Therapeutics, Inc. (NASDAQ:SAGE) – Analysts at William Blair cut their FY2018 earnings per share estimates for Sage Therapeutics in a research note issued on Tuesday. William Blair analyst T. Lugo now expects that the biopharmaceutical company will post earnings per share of ($6.70) for the year, down from their prior estimate of ($6.03). William Blair also issued estimates for Sage Therapeutics’ FY2019 earnings at ($5.15) EPS.

SAGE has been the topic of a number of other research reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $91.00 price objective (down previously from $104.00) on shares of Sage Therapeutics in a report on Wednesday. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Sage Therapeutics in a report on Thursday, August 31st. Cowen and Company reaffirmed a “buy” rating and set a $100.00 price objective on shares of Sage Therapeutics in a report on Friday, August 4th. BidaskClub lowered Sage Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, HC Wainwright upped their price objective on Sage Therapeutics to $86.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $84.25.

TRADEMARK VIOLATION WARNING: “William Blair Comments on Sage Therapeutics, Inc.’s FY2018 Earnings (SAGE)” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/14/william-blair-comments-on-sage-therapeutics-inc-s-fy2018-earnings-sage.html.

Shares of Sage Therapeutics (SAGE) traded down 8.91% on Thursday, hitting $64.10. The stock had a trading volume of 1,084,060 shares. The firm has a 50 day moving average of $82.79 and a 200 day moving average of $74.97. The stock’s market cap is $2.40 billion. Sage Therapeutics has a 12 month low of $38.30 and a 12 month high of $90.80.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.25). During the same quarter in the previous year, the firm posted ($1.08) earnings per share.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC boosted its position in Sage Therapeutics by 0.3% during the first quarter. FMR LLC now owns 5,590,527 shares of the biopharmaceutical company’s stock worth $397,319,000 after purchasing an additional 15,451 shares in the last quarter. BlackRock Inc. boosted its position in Sage Therapeutics by 5.9% during the second quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock worth $241,431,000 after purchasing an additional 168,424 shares in the last quarter. Vanguard Group Inc. boosted its position in Sage Therapeutics by 2.2% during the second quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock worth $219,006,000 after purchasing an additional 58,679 shares in the last quarter. State Street Corp boosted its position in Sage Therapeutics by 7.7% during the second quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock worth $96,558,000 after purchasing an additional 87,097 shares in the last quarter. Finally, Palo Alto Investors LLC boosted its position in Sage Therapeutics by 9.1% during the first quarter. Palo Alto Investors LLC now owns 1,101,951 shares of the biopharmaceutical company’s stock worth $78,316,000 after purchasing an additional 92,021 shares in the last quarter.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.